Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Deferoxamine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 631 records · Page 35Linked to original sources
PubMed1990

[Evaluation of thrombus scintigraphy using 67Ga-deferoxamine-dialdehydestarch-fibrinogen in patients with internal A-V shunt].

We evaluated the diagnosis of thrombus and the effect of antithrombic therapy by using 67Ga-DFO-DAS-Fibrinogen (67Ga-Fbg.) scintigraphy in vivo. The 11 patients with chronic renal failure had the operation of the internal A-V shunt. The two groups were divided the group I (the patients were injected 67Ga-Fbg. within 5 days after the operation of A-V shunt) from the group II (the patients were injected 67Ga-Fbg. from 7 months to 6 years after A-V shunt). We examined 72 h after the injection of 67Ga-Fbg. in all patients. In group I, the scintigraphy showed the deposition of 67Ga-Fbg. in all 5 patients, but 3 patients were given dipyridamole (75-300 mg). The scintigraphy examined 3 weeks after A-V shunt were negative in 2 patients in group I. In group II, the scintigraphy showed the deposition of 67Ga-Fbg. in the two of 6 patients. Within 5 day after A-V shunt, we observed there was the tendency of the thrombus formation. The scintigraphy of 67Ga-Fbg. was useful for the detection of thrombus in vivo.

Adolescent↗
PubMed1998

[Experimental studies of the protective effect of deferoxamine mesilate on cisplatin induced toxicity].

Cisplatin (CDDP) is an antitumor agent against several types of neoplasms. It has, however, various side effects such as nephrotoxicity and ototoxicity. Several efforts have been made to prevent these toxic side effects. On the other hand, deferoxiamine mesilate (DFO), an iron-chelating agent, has been used for iron-overloaded patients. Since the 1980s, many authors have reported DFO-associated hearing impairment. Some experimental data suggest that DFO itself was responsible for ototoxicity. In addition, it has also been recognized that DFO can act as a free radical scavenger. Experimental trials using DFO are also expected to prevent CDDP-induced toxicity because its generation mechanism is thought to be associated with free radical formation. The present study was planned to investigate whether DFO, which might be an ototoxic agent, had a protective effect against various CDDP-induced toxicities including ototoxicity. Fisher rats were used in this study and were divided into four groups: 1) Group I, a vehicle control, 2) Group II, animals receiving 100 mg of DFO per kg, 3) Group III, animals administered 0.9 mg of CDDP per kg alone and 4) Group IV, animals receiving 100 mg of DFO per kg 60 min before 0.9 mg of CDDP per kg for 10 days. First, the protective effect of DFO against CDDP-induced ototoxicity was studied. The auditory threshold was determined by using the compound action potential (CAP) from the round window membrane. CAPs were recorded on the 5th day after completion of drug administration. Then CAPs recording, cochlear sensory epithelia were observed over all the turns of the cochlea by scanning electron microscopy. There were no significant differences in CAP thresholds between Group I and IV, though the thresholds in Group III were significantly higher at 16 kHz and 20 kHz than those in Group IV. The rate of missing outer hair cells in Group IV was significantly lower than that in Group III. The results clearly demonstrated that DFO had a protective effect against CDDP-induced ototoxicity. Second, the protective effect of DFO against CDDP-induced nephrotoxicity was studied. Renal function was evaluated by measuring blood urea nitrogen (BUN) and serum creatinine (Cr) levels. Both BUN and Cr levels in Group IV were significantly lower than those in Group III. The data suggested that DFO preadministration prevented CDDP-induced nephrotoxicity. Third, the influence of DFO on the antitumor activity of CDDP was investigated in rats inoculated with squamous cell carcinoma cells (SCC-131) subcutaneously. The influence of drugs was determined by measuring the tumor growth rate. There was no difference in the tumor growth rate between Group III and IV. The result revealed that DFO had no influence on CDDP antitumor activity. In conclusion, the above results demonstrating that DFO preadministration can prevent both CDDP-induced ototoxicity and nephrotoxicity without attenuation of CDDP antitumor activity, suggest the usefulness of CDDP antitumor chemotherapy.

Animals↗
PubMed2002

Iron chelation via deferoxamine exacerbates experimental salmonellosis via inhibition of the nicotinamide adenine dinucleotide phosphate oxidase-dependent respiratory burst.

Competition for cellular iron (Fe) is a vital component of the interaction between host and intracellular pathogen. The host cell requires Fe for the execution of antimicrobial effector mechanisms, whereas most bacteria have an obligate requirement for Fe to sustain growth and intracellular survival. In this study, we show that chelation of host Fe in vivo exacerbates murine salmonellosis, resulting in increased bacterial load and decreased survival times. We further demonstrate that host Fe deprivation results in an inability to induce the NADPH oxidase-dependent production of reactive oxygen, an essential host defense mechanism for the early control of Salmonella typhimurium infection. Thus, altering the equilibrium of intracellular Fe influences the course of infection to the benefit of the pathogen.

Animals↗
PubMedDate not supplied

[Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].

The optimal control of aluminium content in dialysis fluids has resulted in a decrease in the incidence of aluminium related bone disease (ARBD) and in the risk for aluminium toxicity. Nevertheless the problem has not disappeared. Bone biopsy with specific staining for Al remains the only reliable method for the diagnosis of ARBD. Currently there is not a total agreement on the reliability of serum Al levels and of the DFO test in the identification of patients with Al overload or toxicity. In a series of patients (mean age 48 +/- 14 years old) from our hemodialysis units we carried out bone biopsy and we studied the prevalence of bone aluminium overload and of ARBD and the usefulness of serum aluminium and of DFO test in their diagnosis. Seventy- three bone biopsies were evaluated by histomorphometric analysis and aluminium staining (Aluminon). Al overload was diagnosed when the Aluminon staining was positive independent of the bone surface covered with Al and of the bone formation rate (BFR). Patients were consider to have ARBD when aluminium covered > 25% of bone surface and BFR was < 0.031 micron 3/micron 2/day. Fifteen patients had aluminium overload while 7 patients were considered to have ARBD. Positive Aluminon staining appeared in all histopathological forms of renal osteodystrophy although it appeared mainly in patients with mixed lesion and osteomalacia. Most of the patients with adynamic bone disease had negative Aluminon staining. Patients with aluminium overload showed lower bone formation and mineralization rates. Serum aluminium levels below 40 micrograms/l were useful to exclude bone aluminium overload. Serum aluminium levels and DFO test were not specific in diagnosing aluminium overload or ARBD. A DFO test with an increment in serum aluminium over 100 micrograms/l in combination with a serum PTH below 200 pg/ml was useful to diagnose ARBD.

Adult↗
PubMed2001

[Effects of aluminum and deferoxamine on concentration of essential elements in animals experimentally intoxicated with aluminum].

To assess the effect of aluminium intoxication in tissues of experimental animals on Ca, Mg, Zn, Cu, and Fe concentration, aluminium nitrate was administered intraperitoneally to mice at a daily dose of 0.27 mMol/kg for 5 weeks. Concentration of Al, Ca, Mg, Zn, Cu, and Fe were analyzed by atomic absorption spectrometry. The Al content in liver and tibia was significantly higher in treated mice in comparison with control group. In Al loaded tissues the significant increase of all tested essential elements was found. To evaluate the results of DFO treatment on essential elements, mice received 6 times intraperitoneally 3.5 mMol/kg of DFO. This treatment had generally no effect on reduction of Al concentration in tibia and liver, as well as on changes in essential elements concentration.

Aluminum Compounds↗
PubMed2004

Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.

BACKGROUND AND OBJECTIVES: Seven Italian centers reported data on survival, causes of death and appearance of complications in patients with thalassemia major. The interactions between gender, birth cohort, complications, and ferritin on survival and complications were analyzed. DESIGN AND METHODS: Survival after the first decade was studied for 977 patients born since 1960 whereas survival since birth and complication appearance was studied for the 720 patients born after 1970. Better survival was demonstrated for patients born in more recent years (p<0.00005) and for females (p=0.0003); 68% of the patients are alive at the age of 35 years. In the entire population 67% of the deaths were due to heart disease. RESULTS: There was a significant association between birth cohort and complication-free survival (p<0.0005). The prevalence of complications was: heart failure 6.8%, arrhythmia 5.7%, hypogonadism 54.7%, hypothyroidism 10.8%, diabetes 6.4%, HIV infection 1.7%, and thrombosis 1.1%. Lower ferritin levels were associated with a lower probability of heart failure (hazard ratio =3.35, p<0.005) and with prolonged survival (hazard ratio = 2.45, p<0.005), using a cut-off as low as 1,000 ng/mL. INTERPRETATION AND CONCLUSIONS: Survival and complication-free survival of patients with thalassemia major continue to improve, especially for female patients born shortly before or after the availability of iron chelation.

Adult↗